Table 2.

Clinicopathogical characteristics and molecular profile of the 14 patients

Sample ID	Sex	Age	TNM stage	Resection	Systemic treatments	Survival time	Recommended treatments	Treatments to avoid	Increased risk of toxicity
EUP100	F	63	T3N1M0	Total pancreatectomy, splenectomy, vascular resection (SMV + CHA), R1	Gemcitabine FL‐Oxa	18 months, 17 days	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor IGF‐1R antibody + Temsirolimus	Single agent RTK‐inhibitors Everolimus	Cisplatin Cyclophosphamide
EUP101	M	70	T3N1M0	Whipple, R1	Gemcitabine FL‐Oxa	10 months, 17 days	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor	Single agent RTK‐inhibitors Everolimus Imatinib	Capecitabine Cisplatin Cyclophosphamide
EUP102	F	65	T3N0M0	Whipple, R1	Gemcitabine	36 months, 2 daysa	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor	Single agent RTK‐inhibitors Everolimus	Trastuzumab Capecitabine Cisplatin Cyclophosphamide Paclitaxel
EUP103	F	67	T3N1M0	Whipple, vascular resection (PV), R1	Gemcitabine Irinotecan + capecitabine	10 months, 22 days	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor	Single agent RTK‐inhibitors Imatinib Everolimus	Paclitaxel Trastuzumab Capecitabine
EUP104	F	81	T3N1M0	Whipple, R1	None	14 months, 23 days	Trametinib AKT inhibitor MEK + PK inhibitor IGF‐1R antibody + Temsirolimus	Single agent RTK‐inhibitors Everolimus	Cisplatin Mercaptopurine Thioguanine Trastuzumab
EUP105	M	65	T3N1M0	Whipple, R0	None	16 months, 1 day	Trametinib AKT inhibitor MEK + PK inhibitor IGF‐1R antibody + Temsirolimus	Single agent RTK‐inhibitors Everolimus	Capecitabine Cisplatin Cyclophosphamide
EUP106	M	59	T3N1M1	Whipple, R0	Gemcitabine	6 months, 18 days	Paclitaxel Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor IGF‐1R antibody + Temsirolimus Epirubicin	Single agent RTK‐ inhibitors Everolimus Gefitinib	Capecitabine Cisplatin Cyclophosphamide
EUP107	K	66	T3N1M0	Total pancreatectomy, R1	Gemcitabine	15 months, 23 days	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor	Single agent RTK‐inhibitors Everolimus	Capecitabine
EUP108	M	50	T3N1M0	Whipple, R1	Gemcitabine FL‐Oxa	9 months, 1 day	Trametinib + Docetaxel AKT inhibitor MEK + PK inhibitor	Single agent RTK‐inhibitors Everolimus	Capecitabine
EUP109	F	75	T3N1M0	Whipple, R1	None	6 months, 7 days	Trametinib + Docetaxel	Single agent RTK‐inhibitors Everolimus	Cisplatin Cyclophosphamide
EUP110	M	62	T3N1M0	Whipple, R1	Gemcitabine GemCap	32 months, 24 days	Trametinib + Docetaxel Imatinib Epirubicin	Single agent RTK‐inhibitors Everolimus Doxorubicin	Capecitabine Mercaptopurine Thioguanine Trastuzumab Cisplatin Cyclophosphamide
EUP067	F	42	T4N1M1	None	FOLFIRINOX Gemcitabine/Abraxane	14 months, 22 days	Lapatinib + Docetaxel	None	Capecitabine
EUP122	M	64	T4N0M0	Distal pancreatectomy, splenectomy, gastrectomy, vascular resection (CHA), R0	GemCap	34 months, 1 daya	None	None	Paclitaxel Methotrexate Tamoxifen
EUP186	M	51	T3N0M0	Distal pancreatectomy, R1	GemCap FOLFIRINOX	47 months, 17 daysa	FOLFOX FOLFIRINOX MEK inhibitors HSP90 inhibitors PI3K/AKT inhibitors	Singbgble agent RTK Inhibitors Everolimus	Paclitaxel

^aAlive as of October 2016.